Diverse Psychotropic Substances Detected in Drug and Paraphernalia Samples Submitted to Drug Checking Services in Toronto, Ontario, Canada, October 2019-April 2020

Kristy Scarfone  
St Michael's Hospital Li Ka Shing Knowledge Institute

Nazlee Maghsoudi  
St Michael's Hospital Li Ka Shing Knowledge Institute

Karen McDonald  
St Michael's Hospital Li Ka Shing Knowledge Institute

Cristiana Stefan  
CAMH: Centre for Addiction and Mental Health

Daniel R Beriault  
St Michael's Hospital

Ernest Wong  
CAMH: Centre for Addiction and Mental Health

Mark Evert  
St Michael's Hospital

Shaun Hopkins  
Toronto Public Health

Peter Leslie  
Toronto Harm Reduction Alliance

Tara Marie Watson  
CAMH: Centre for Addiction and Mental Health

Dan Werb  
University of California San Diego  
https://orcid.org/0000-0003-0614-9386

Brief report

**Keywords:** drug overdose, fentanyl, etizolam, flualprazolam, synthetic cannabinoid

**Posted Date:** July 26th, 2021

**DOI:** https://doi.org/10.21203/rs.3.rs-694379/v1
Abstract

Background

The opioid overdose crisis has generated innovative harm reduction and drug market monitoring strategies. In Toronto, Ontario, Canada, a multi-site drug checking service (DCS) pilot project was launched in October 2019. The project provides people who use drugs with information on the chemical composition of their substances, thereby increasing their capacity to make more informed decisions about their drug use and avoid overdose. DCS also provides real-time market monitoring to identify trends in the unregulated drug supply.

Methods

Sample data were obtained through analyses of drug and used paraphernalia samples submitted anonymously and free of charge to DCS in downtown Toronto from October 10, 2019 to April 9, 2020, representing the first six months of DCS implementation. Analyses were conducted in clinical laboratories using ultra high performance liquid chromatography-high resolution mass spectrometry (UPLC-HRMS), and liquid chromatography or gas chromatography-mass spectrometry (LC-MS, GC-MS) techniques.

Results

Overall, 555 samples were submitted, with 49% (271) of samples that were found to contain high-potency opioids, of which 87% (235) also contained stimulants. Benzodiazepines or related drugs were also found in 21% (116) of all samples, and synthetic cannabinoids in 1% (7) of all samples. Negative effects (including overdose) were reported for 12% (69) of samples submitted for analysis.

Conclusions

Toronto's DCS identified a range of high-potency opioids with stimulants, benzodiazepines and related drugs, and a synthetic cannabinoid, AMB-FUBINACA. This information can inform a range of evidence-informed overdose prevention efforts.

Introduction

The opioid overdose crisis is worsening throughout much of North America, particularly in Canada and the United States.\(^1\),\(^2\) Between January 2016 and March 2020, more than 16,364 Canadians died from apparent opioid-related overdoses.\(^3\) Recent estimates suggest that 1 in 6 deaths of Ontarians aged 25-34 years is related to opioid overdose.\(^4\) Moreover, the incidence of fatal overdose has increased in Ontario since the imposition of COVID-19 restrictions in March 2020.\(^5\)

The dynamic uncertainty in the unregulated drug market has generated innovative harm reduction approaches in Canada, including the implementation of drug checking services (DCS) tailored for structurally vulnerable people who use drugs.\(^6\) Originating in California amid the counterculture
movement in the 1960s and early 1970s\textsuperscript{7} and having later gained popularity in the 1990s in European nightlife and dance settings\textsuperscript{8}, DCS provide chemical analysis of substances to clients while contributing data to drug market monitoring.\textsuperscript{9}

A multi-site DCS pilot was launched in Toronto, Ontario, Canada in October 2019.\textsuperscript{10} Intake sites are co-located with supervised consumption services (SCS) at multiple harm reduction agencies. The project prioritizes providing structurally vulnerable (i.e., socially and economically marginalized) people who use drugs with information about the composition of their substances, thereby increasing their capacity to avoid overdose.

This report presents early trends of samples analyzed within the first six months of DCS implementation in Toronto (October 10, 2019-April 9, 2020). We sought to identify the prevalence of high-potency opioids in combination with stimulants, benzodiazepines and related drugs, and synthetic cannabinoids. We also present data on reported negative effects of samples.

**Methods**

The protocol and rationale for the evaluation of Toronto’s DCS has previously been described.\textsuperscript{10} In brief, we are evaluating the impact of Toronto’s DCS on overdose and related risk behaviors among clients and its capacity to identify trends in the chemical composition of Toronto’s unregulated drug supply. The results presented herein were obtained through chemical analyses of samples submitted anonymously and free of charge to DCS. Samples are analyzed using ultra high performance liquid chromatography-high resolution mass spectrometry (UPLC-HRMS), and liquid and gas chromatography-mass spectrometry (LC-MS, GC-MS) techniques, which are the gold standards in forensic drug analysis.\textsuperscript{11}

Results are provided within one to two business days. Aggregated results are publicly shared online (drugchecking.cdpe.org).\textsuperscript{12} The analytical results are supplemented by data from surveys administered during sample collection, including drug expectation, the reuse of paraphernalia, and negative effects post-use.

**Results**

Overall, 555 samples were submitted for analysis by DCS, among which 63\% (n=349) were substances (i.e., liquid, pill, powder) and 37\% (n=206) paraphernalia (i.e., cooker, filter). 10\% (n=21) of which reportedly reused. The number of samples stratified by type and category of drug detected are presented in Figure 1.

**Negative effects**

Survey responses indicate that 12\% (n=69) of all samples submitted for analysis by the DCS were associated with negative effects. Of these samples, survey responses report that: 54\% (n=37) were
implicated in an overdose, 29% (n=20) were associated with feeling unwell, 7% (n=5) were associated with drowsiness, 7% (n=5) had a stronger effect than anticipated, and 3% (n=2) had little or no effect.

**Expected opioids and detected contents**

An opioid was expected in 49% (n=272) of all samples. Fentanyl was expected most often, in 94% (n=256) of all expected opioids. **Figure 2** depicts the detected drugs found in samples expected to contain opioids upon submission, including unexpected high potency opioids, unexpected benzodiazepines-type drugs, and unexpected synthetic cannabinoids.

**Presence of stimulants with high-potency opioids**

A high potency opioid (i.e., fentanyl, fentanyl-related drugs, carfentanil) was detected in 49% (n=271) of all samples submitted for analysis by the DCS. In 87% (n=235) of these samples where a high potency opioid was detected, one or more stimulants were found in combination. Of this fraction of samples, a high-potency opioid (i.e., fentanyl, carfentanil) was expected in 216 samples, or 92%. Caffeine was the most commonly co-detected stimulant in 79% (n=215). The most frequent combinations detected were fentanyl with caffeine (n=215), with cocaine (n=61), with methamphetamine (n=43), and with cocaine-related drugs such as anhydroecgonine methyl ester (AEME), benzylecgonine, and methylecgonine (n=34). In all samples where a high potency was detected with at least one stimulant, the stimulant was not reported to be an expected substance upon submission and are thereby appearing unexpected in expected high potency opioid samples.

**Presence of benzodiazepine-type drugs**

At least one benzodiazepine-type drug was detected in 21% (n=116) of all samples submitted for analysis. Of these samples, 67% (n=78) contained only one benzodiazepine and 33% (n=38) contained two or more. Majority of the detected benzodiazepines were found unexpectedly in submitted samples; only 13% (n=15) were expected to contain benzodiazepines. Fentanyl was expected in 80% (n=93), and various other drugs in the remaining 7% (n=8). The primary benzodiazepine-type drugs detected were etizolam (n=95), flualprazolam in (n=46), alprazolam (Xanax) (n=9), and flubromazolam (n=4). Samples containing benzodiazepine-type drugs account for 21% (n=24) of samples associated with a negative effect, 22 of which were implicated in an overdose.

**Presence of synthetic cannabinoids**

AMB-FUBINACA was the only synthetic cannabinoid detected. It was found in 1% (n=7) of all samples, all of which were expected to contain fentanyl.

**Discussion**

Across a six-month period in Toronto, a large proportion of samples submitted to DCS contained high-potency opioids presenting with unexpected stimulants. We also detected various benzodiazepine-type
drugs and a synthetic cannabinoid, AMB-FUBINACA.

The prevalence of high-potency opioids is noteworthy given that they carry increased risk for overdose. Caffeine was the most common stimulant co-presenting with high-potency opioids, which is consistent with other settings.\textsuperscript{13} To our knowledge no published scientific literature exists regarding the impact of intravenous administration of caffeine in a non-clinical setting. Further research is required to clinically assess the potential contribution of caffeine injection to overdose or other adverse events.

The detection of various benzodiazepine-type drugs is significant given the risk of overdose that they present, especially when unexpected and combined with opioids. Benzodiazepines elicit sedative and anxiolytic effects that, when combined with other central nervous system depressants, may amplify cardiovascular and respiratory depression and contribute to overdose severity.\textsuperscript{14} Compounding this issue is the lack of reliable and effective antagonist therapies to reverse benzodiazepine overdose outside of clinical settings.\textsuperscript{15} Additionally, increased use of benzodiazepines may increase tolerance and the potential for withdrawal, especially if individuals are not aware that they are using these substances. This issue therefore demands greater urgency as it appears to be contributing to overdose mortality in Toronto and elsewhere.\textsuperscript{16} For instance, on February 26, 2020, a notable spike in overdoses (16 in seven hours) in Toronto was associated with drug samples containing large proportions of flualprazolam along with fentanyl and caffeine.\textsuperscript{17}

We also detected AMB-FUBINACA, an ultra-potent synthetic cannabinoid that can be up to hundreds of times more potent than D9-tetrahydrocannabinol.\textsuperscript{18} Synthetic cannabinoid exposure may cause adverse effects including neuropsychiatric, cardiovascular, and renal impairment\textsuperscript{18}, but the effects of co-administration of AMB-FUBINACA and other central nervous system depressants (e.g., benzodiazepines, opioids) remain largely unknown. It is therefore critical to share information on their presentation in unregulated drug markets with people who use drugs, harm reduction workers, and clinicians.

There are limitations to the capacity of Toronto’s DCS to provide a comprehensive analytical assessment of the unregulated drug supply. Inherent limitations of mass spectrometry analysis include accessibility, cost, destruction of the sample during analysis, contaminants obscuring data outputs, the speed at which results can be provided to clients, and the inability to detect certain non-drug compounds (e.g., metals, pesticides, inorganic salts, sugars).\textsuperscript{11} With regards to sample composition, the results may not represent the entire supply that samples are taken from, and reused paraphernalia may contain substances from multiple uses.

Conclusions

This report briefly highlights the presence of highly-potent substances and combinations thereof in Toronto’s unregulated drug market. Timely data and public health alerts are critical to inform people who may experience health harms from drug use and demonstrate the value of DCS for drug market
monitoring. Examples of such alerts were issued by Toronto Public Health regarding noteworthy trends in Toronto's unregulated drug supply.\textsuperscript{12}

However, DCS alone are insufficient to prevent overdose and mortality arising from an unregulated drug supply, especially among persons without access to medication-assisted treatment for drug dependence or other standard-dose regimens as a result of drug policies (e.g., drug criminalization) that amplify social marginalization.\textsuperscript{19} Quantifying the persisting contaminated drug supply and addressing it with policy solutions such as safer supply or other standard-dose modalities is therefore urgently needed.\textsuperscript{20}

As the global COVID-19 pandemic continues, drug trafficking patterns and supply are likely to remain dynamic.\textsuperscript{21} This increases the need to sustain and expand DCS to prevent overdose, and to monitor drug market fluctuations.

\section*{Declarations}

\textbf{Ethics Approval and Consent to Participate:}

Research Ethics Board approval has been obtained for this research study from Unity Health Toronto, Toronto Public Health, Centre for Addiction and Mental Health, and University of Toronto.

\textbf{Consent for Publication:}

While informed consent is obtained from participants for this study, the present manuscript does not publish any identifiable personal data or images.

\textbf{Availability of Data and Material:}

A selection of the data presented herein is available online at: https://drugchecking.cdpe.org/

\textbf{Competing Interests:}

The authors declare that they have no conflicts of interest.

\textbf{Funding:}

Toronto's Drug Checking Service is supported by an operating grant from Health Canada's Substance Use and Addictions Program (Award #1718-HQ-000027, Recipient: Dan Werb, PhD) and the St. Michael's Hospital Foundation. Dan Werb is supported by the Canadian Institutes of Health Research via a New Investigator Award, and the Ontario Ministry of Research, Innovation and Science via an Early Researcher Award. Nazlee Maghsoudi is supported by a CIHR Vanier Canada Graduate Scholarship.

\textbf{Author's Contributions:}
Laboratory analysis data was generated by CS, DRB, EW, and ME. DW, NM, and KM conceptualized the paper. KS drafted the manuscript and figures. All authors reviewed and provided substantive input on the manuscript. All authors read and approved the final manuscript.

**Acknowledgements:**

We wish to acknowledge our partnering harm reduction agencies - Parkdale Queen West Community Health Centre (Queen West site), South Riverdale Community Health Centre, and The Works at Toronto Public Health, and partnering clinical laboratories (Centre for Addiction and Mental Health and St. Michael's Hospital). We thank the members of the Community Advisory Board for Toronto's DCS for their guidance. We also thank those who trusted us with their samples and provided feedback on the service.

Toronto’s DCS is supported by an operating grant from Health Canada’s Substance Use and Addictions Program and the St. Michael's Hospital Foundation. Dan Werb is supported by the Canadian Institutes of Health Research via a New Investigator Award, and the Ontario Ministry of Research, Innovation and Science via an Early Researcher Award. Nazlee Maghsoudi is supported by a CIHR Vanier Canada Graduate Scholarship.

We acknowledge that the land on which we conduct our research is the traditional territory of many nations including the Mississaugas of the Credit, the Anishinaabe, the Chippewa, the Haudenosaunee, and the Wendat peoples, now also home to many diverse First Nations, Inuit, and Métis peoples.

**References**


**Figures**

![Figure 1](image)

**Figure 1**

Graphical depiction of sample types stratified by category of drug detected (i.e., benzodiazepine, synthetic cannabinoid, or high-potency opioid) compared to total number of samples in that category (N=555)
Figure 2

A breakdown of detected high-potency opioids, benzodiazepines or related drugs, and synthetic cannabinoids as drugs found in samples expected to contain variable opioids (n=272)

*Other: Oxycodone (3), O-Desmethyltramadol (1)